Vertex Pharmaceuticals Incorporated

193.02-23.75-10.96%Vol 13.70M1Y Perf -26.54%
Jun 11th, 2021 16:00 DELAYED
BID193.02 ASK193.30
Open194.04 Previous Close216.77
Pre-Market- After-Market193.80
 - -  0.78 0.40%
Target Price
272.61 
Analyst Rating
Strong Buy 1.40
Potential %
41.23 
Finscreener Ranking
★★★★★     60.44
Insiders Trans % 3/6/12 mo.
-100/-100/-97 
Value Ranking
★★★★★     61.85
Insiders Value % 3/6/12 mo.
-100/-100/-87 
Growth Ranking
★★★★★     81.02
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-86 
Income Ranking
 —    -
Market Cap49.97B 
Earnings Rating
Sell
Price Range Ratio 52W %
0.12 
Earnings Date
29th Jul 2021

Today's Price Range

192.88200.05

52W Range

192.88306.08

5 Year PE Ratio Range

-159.40185.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.06%
1 Month
-9.24%
3 Months
-9.94%
6 Months
-13.90%
1 Year
-26.54%
3 Years
27.84%
5 Years
110.97%
10 Years
300.46%

TickerPriceChg.Chg.%
VRTX193.02-23.7500-10.96
AAPL127.351.24000.98
GOOG2 513.93-7.6700-0.30
MSFT257.890.65000.25
XOM62.17-0.5800-0.92
WFC45.680.59001.31
JNJ164.96-2.1200-1.27
FB331.26-1.2000-0.36
GE13.690.06000.44
JPM160.29-0.1100-0.07
Financial StrengthValueIndustryS&P 500US Markets
4.10
4.90
0.06
0.06
56.00
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
88.10
52.10
53.80
20.60
43.16
RevenueValueIndustryS&P 500US Markets
6.41B
24.78
34.19
34.61
Earnings HistoryEstimateReportedSurprise %
Q01 20212.382.546.72
Q04 20202.332.22-4.72
Q03 20202.022.3616.83
Q02 20201.752.2629.14
Q01 20201.562.2141.67
Q04 20190.961.4450.00
Q03 20190.870.9711.49
Q02 20190.750.9932.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR2.29-4.98Negative
9/2021 QR2.22-10.12Negative
12/2021 FY9.41-2.79Negative
12/2022 FY10.34-2.91Negative
Next Report Date29th Jul 2021
Estimated EPS Next Report2.29
Estimates Count6
EPS Growth Next 5 Years %11.90
Volume Overview
Volume13.70M
Shares Outstanding258.87M
Trades Count156.86K
Dollar Volume415.67M
Avg. Volume1.96M
Avg. Weekly Volume4.08M
Avg. Monthly Volume2.16M
Avg. Quarterly Volume1.77M

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stock closed at 193.02 per share at the end of the most recent trading day (a -10.96% change compared to the prior day closing price) with a volume of 13.72M shares and market capitalization of 49.97B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3400 people. Vertex Pharmaceuticals Incorporated CEO is Reshma Kewalramani.

The one-year performance of Vertex Pharmaceuticals Incorporated stock is -26.54%, while year-to-date (YTD) performance is -18.33%. VRTX stock has a five-year performance of 110.97%. Its 52-week range is between 192.88 and 306.08, which gives VRTX stock a 52-week price range ratio of 0.12%

Vertex Pharmaceuticals Incorporated currently has a PE ratio of 20.00, a price-to-book (PB) ratio of 6.05, a price-to-sale (PS) ratio of 8.44, a price to cashflow ratio of 16.40, a PEG ratio of 2.32, a ROA of 25.60%, a ROC of 33.22% and a ROE of 34.84%. The company’s profit margin is 43.16%, its EBITDA margin is 53.80%, and its revenue ttm is $6.41 Billion , which makes it $24.78 revenue per share.

Of the last four earnings reports from Vertex Pharmaceuticals Incorporated, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $2.29 for the next earnings report. Vertex Pharmaceuticals Incorporated’s next earnings report date is 29th Jul 2021.

The consensus rating of Wall Street analysts for Vertex Pharmaceuticals Incorporated is Strong Buy (1.4), with a target price of $272.61, which is +41.23% compared to the current price. The earnings rating for Vertex Pharmaceuticals Incorporated stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Vertex Pharmaceuticals Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Vertex Pharmaceuticals Incorporated has a Sell technical analysis rating based on Technical Indicators (ADX : 6.76, ATR14 : 5.54, CCI20 : -318.54, Chaikin Money Flow : -0.31, MACD : -2.00, Money Flow Index : 34.68, ROC : -7.54, RSI : 28.90, STOCH (14,3) : 0.57, STOCH RSI : 0.00, UO : 31.28, Williams %R : -99.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Vertex Pharmaceuticals Incorporated in the last 12-months were: Amit K. Sachdev (Option Excercise at a value of $167 935), Amit K. Sachdev (Sold 19 296 shares of value $4 216 614 ), Bastiano Sanna (Sold 4 444 shares of value $949 980 ), Bruce I. Sachs (Buy at a value of $3 260 464), Charles F. Wagner (Sold 700 shares of value $205 206 ), David Altshuler (Option Excercise at a value of $201 592), David Altshuler (Sold 18 545 shares of value $4 081 384 ), Jeffrey M Leiden (Sold 65 584 shares of value $18 766 603 ), Joy Liu (Sold 3 793 shares of value $793 209 ), Michael Parini (Option Excercise at a value of $796 641), Michael Parini (Sold 23 086 shares of value $5 192 713 ), Paul M. Silva (Option Excercise at a value of $295 288), Paul M. Silva (Sold 9 811 shares of value $2 293 904 ), Sangeeta N. Bhatia (Option Excercise at a value of $1 105 789), Sangeeta N. Bhatia (Sold 10 516 shares of value $2 805 518 ), Stuart A. Arbuckle (Option Excercise at a value of $1 021 039), Stuart A. Arbuckle (Sold 42 673 shares of value $9 394 299 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
16 (76.19 %)
15 (75.00 %)
13 (68.42 %)
Moderate Buy
1 (4.76 %)
1 (5.00 %)
2 (10.53 %)
Hold
4 (19.05 %)
4 (20.00 %)
4 (21.05 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.42
Strong Buy
1.50

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Inc discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. The company's pipeline also includes genetic therapies like CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. In addition, Vertex is focusing on developing therapies for pain, type 1 diabetes, inflammatory diseases, influenza, and other rare diseases.

CEO: Reshma Kewalramani

Telephone: +1 617 341-6100

Address: 50 Northern Avenue, Boston 02210, MA, US

Number of employees: 3 400

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

61%39%

Bearish Bullish

55%45%

Bearish Bullish

59%41%

News

Stocktwits